ClinicalTrials.gg
CompletedNCT02472912Updated Mar 11, 2022

Adalimumab PK Bioequivalence Study to EU and US Sourced Humira

A Phase 1 interventional study of BMO-2 and EU-Humira in Healthy Volunteers, sponsored by Mylan Inc.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-11.

Sponsored by Mylan Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Double-Blind, 3-Way Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of BMO-2 to EU and US Sourced Humira® Administered as a Single Dose (40 mg) Subcutaneous Injection in Healthy Adults.

Read the detailed description

This is a single-center, randomized, double-blind, 3-way parallel study in 270 healthy adult male and female subjects. During this study, the PK bioequivalence of BMO-2, containing 40 mg adalimumab, will be compared to EU licensed Humira® (EU-Humira® ) (40 mg) and US licensed Humira® (US-Humira® ) (40 mg).

Randomization will be stratified by body weight (weight categories of 60.0-79.9 kg and 80.0-95.0 kg). After randomization, subjects will receive one of the following treatments: a single sc injection of 40 mg BMO-2, an equivalent sc injection of EU-Humira® (40 mg), or an equivalent sc injection of US-Humira® (40 mg).

Volunteers participation in the study is expected to finish with the follow-up visit, scheduled 70 days after the injection of study drug.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pharmacokinetics
  • Adalimumab
  • Biosimilar Pharmaceuticals
03

In context

Lead sponsor

Mylan Inc. is the lead sponsor of 44 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.

First submitted before Mylan Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight: 60.0-95.0 kg.
  • (BMI) : 19.0-30.0 kg/m2, inclusive
  • Medical history without major pathology.
  • Systolic blood pressure ≤150 mmHg and diastolic blood pressure ≤90 mmHg.
  • Computerized (12-lead) (ECG) recording without signs of pathology
  • Nonsmoker or light smoker
  • Ability and willingness to abstain from alcohol from 48 h prior to drug administration and 48h prior to ambulatory visits, and during the stays in the clinical research center until discharge from the in-house period.
  • Fertile males and females participating in heterosexual sexual relations:willingness to use adequate from screening until 90 days after the follow-up visit
  • Females must not lactate and must have a negative pregnancy test at screening and at admission
  • Differentiation of leukocytes, count, hematocrit and results within the reference ranges. Minor deviations considered to lack any clinical relevance by the Principal Investigator can be accepted.
  • All other values for hematology and for biochemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Principal Investigator.

Other protocol-defined inclusion/exclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • History of relevant drug and/or food allergies.
  • to Humira® or its constituents.
  • Known history of previous exposure to anti TNF-alpha molecules.
  • Any past or concurrent medical conditions potentially increasing the subject's risks. Examples of these include medical history with evidence of pathology (e.g., , demyelinating disorders).
  • Presence of (COPD). Asthma in the childhood is allowed
  • Any current active infections, including localized infections, or any recent history
  • Treatment with non-topical medications (including over the counter medication, and herbal remedies such as St. John's Wort extract) within 7 days prior to study drug administration, with the exception of hormonal , multivitamins, vitamin C, food supplements and a limited amount of acetaminophen, which may be used throughout the study.
  • History of active tuberculosis or presence of active or latent tuberculosis.
  • Having resided or traveled in regions where tuberculosis and mycosis are endemic within 90 days before screening, or who intend to visit such a region during the period of 3 months after dosing.
  • Having received during the past 4 weeks before screening or have the intention to receive vaccination during the study.
  • Participation in a drug study within 60 days or 5 half-lives of the previous drug (if known), whichever is longer, prior to drug administration
  • Donation of more than 500 mL of blood within 8 weeks prior to drug administration.
  • History of alcohol abuse or drug addiction (including soft drugs like cannabis products).
  • Positive urine drug screen (opiates, methadone, cocaine, amphetamines (including XTC or metamphetamines), cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants) and positive alcohol breath test.
  • Positive screen on surface antigen (HBsAg), anti- virus antibodies (HCV), or anti- 1/2 antibodies (HIV).

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    Treatment A

    Single Injection of 40mg / 0.8 mL BMO-2

    Biological: BMO-2

  • Active comparator
    Treatment B

    Single Injection of 40mg / 0.8 mL EU-Humira

    Biological: EU-Humira

  • Active comparator
    Treatment C

    Single Injection of 40mg / 0.8 mL US-Humira

    Biological: US-Humira

Interventions

  • BiologicalBMO-2

    Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).

    Also known as: Adalimumab

  • BiologicalEU-Humira

    Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)

    Also known as: Adalimumab

  • BiologicalUS-Humira

    Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).

    Also known as: Adalimumab

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of adalimumab.

    Time frame: 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71 days post subcutaneous injection.

Secondary outcomes

  1. Frequency of Adverse Events

    Time frame: Up to 71 days.

  2. Safey variable - Tolerability (injection site reactions)

    Tolerability assessments as measured by injection site reactions

    Time frame: Predose and 1, 2, 3, 7, 9, 36, and 71 days post subcutaneous injection.

  3. Safety variable - immunogenicity (Presence of anti-adalimumab antibodies)

    Presence of anti-adalimumab antibodies

    Time frame: Day 1 (pre-dose) and Day 9, 29, and 71 days post subcutaneous injection.

07

Study locations

1 site
  • SGS Belgium NV
    Antwerp, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2015
First posted
Jun 16, 2015
Start
Dec 2014
Primary completionActual
May 2015
CompletionActual
Jun 2015
Last update
Mar 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02472912
Lead sponsor
Mylan Inc.
Collaborators
Mylan GmbH
Responsible party
Sponsor
First posted
Jun 16, 2015
Start date
Dec 2014
Primary completion
May 2015
Completion
Jun 2015
Last update
Mar 11, 2022

Study contacts

Magdalena Petkova, MD
principal investigator · SGS Belgium NV
Fausto Berti
study director · Mylan GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion